James H. Revkin

Associate Clinical Professor of Medicine (Cardiovascular)
Section of Cardiovascular Medicine

Clinical Interests

I am board certified in Cardiovascular Medicine. I am an attending physician for the Yale Heart-Failure, Transplant Cardiology Program.

Reearch Interests

My clinical research efforts have focused on a broad range of areas in cardiovascular medicine, including heart failure, heart transplantation, myocardial metabolism and, diabetes, atherosclerosis, and thrombosis. I direct the US cardiovascular and metabolic diseases clinical research team at Boehringer-Ingelheim, Ridgefield, CT.

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J-C, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, and Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N. Engl J Med. 2007;357:2109-2122.

Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Grobbee DE, Vicari RM, Kastelein JJ. Torcetrapib and progression of carotid intima-media thickness in mixed dyslipidemia. The RADIANCE II study. The Lancet. 2007;370:153-160.

Kastelein JJP, van Leuven S, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, and Bots ML, for the RADIANCE 1 investigators. Effect of torcetrapib on progression of carotid atherosclerosis in heterozygous familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630

Nissen SE, Tardif J-C, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, for the Illustrate Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.

Kastelein JJP, van Leuven S, Evans GW, Riley WA, Revkin JH, Shear CL, and Bots ML, on behalf of the RADIANCE 1 and 2 study investigators. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin 2007; 23: 885–894.

Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG. Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacol Reviews. 2007;59:40-53.

McKenney JM , Davidson M, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below average high-density lipoprotein cholesterol levels, on a background of atorvastatin. J Am Coll Cardiol. 2006;48:1782-1790

Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48:1774-1781.

Schwartz LM, Bukowski TR, Revkin JH, Bassingthwaighte JB. Cardiac endothelial transport and metabolism of adenosine and inosine. Am J Physiol 1999 Sep;277(3 Pt 2):H1241-H1251

Meehan TP, Radford MJ, LVaccarino V, Gottlieb LD, McGovern-Hughes B, Herman MV, Revkin JH, Thierrien ML, Petrillo MK, Krumholz HM. A collaborative project in Connecticut to improve the care of patients with acute myocardial infarction. Jt Comm J Qual Improv 22:751-761, 1996.

Revkin JH and Bravata DM. Cardiogenic pulmonary edema. J Resp Dis 17:444-460, 1996.

Begos DG, Franco KL, Baldwin JC, Lee FA, Revkin JH, and Modlin IM. Optimal timing of cholecystectomy in cardiac transplant patients. World J Surg 19:661-667, 1995.

Young LH, Stirewalt W, McNulty PH, Revkin JH, and Barrett EJ. Effect of insulin on rat heart and skeletal muscle phenylalanyl-tRNA labeling and protein synthesis in vivo. Am J Physiol 267:E337-E342, 1994.

Bukowski TR, Moffett TC, Revkin JH, Ploger JD, and Bassingthwaighte JB. Triple-Label Beta Liquid Scintillation Counting. Analytical Biochemistry 204:171-180, 1992.

Revkin JH. Cardiogenic Shock: An Overview, in Infertility and Reproductive Medicine Clinics of North America (Karlan BY and Surrey ES, eds.) W. B. Saunders Company, Philadelphia. 3: 881-894, 1992.

Allen MD, Denny CF, Kruse AP, Revkin JH, Fishbein DP, and Ashley RL. Limited cytomegalovirus-specific immunoglobulin M and immunoglobulin G profiles in cardiac transplant patients. J Heart Lung Transplant 10:664-73, 1991.

Revkin JH, Young LH, Stirewalt WS, Dahl DM, Gelfand RA, Zaret BL and Barrett EJ. In vivo measurement of myocardial protein turnover using an indicator dilution technique. Circ Res 67(4):902-912, 1990.

Young LH, Jaffe CC, Revkin JH, McNulty PH and Cleman M: Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty. Am J Cardiol 65:986-990, 1990.

Barrett EJ, Revkin JH, Young LH, Zaret BL, Jacob R and Gelfand RA. An isotopic method for measurement of muscle protein synthesis and degradation in vivo. Biochem J 245:223-228, 1987.

Education:	B.A., Williams College 1976 M.D., Brown University, 1981
Training:	Residency: Internal Medicine, Columbia-Presbyterian Medical Center, 1981-84 Clinical Fellow: Cardiovascular Medicine, Yale University, 1984-87 Postdoctoral Fellow: National Simulation Resource Facility, Center for Bioengineering, University of Washington 1987-88
Prior Academic Positions:	Assistant Professor & Director: Transplant Cardiology Program, University of Washington 1988-1990 Assistant Professor & Director: Transplant Cardiology Program, Yale University, 1990-93

Contact

Campus Address
Department of Internal Medicine
Section of Cardiovascular Medicine
Yale University
School of Medicine
Box 208017
New Haven, CT
06520-8017

E-mail
james.revkin@yale.edu

Telephone
203.785.4114